N-Acetyltransferase 2 (NAT 2) Genotyping
Test Code
NAT 2
CPT Codes
83891 x1; 83892 x2; 83900 x1; 83901 x3; 83914 x7; 83909 x1; 83912 x1; 83912-25 x1
Specimen
Whole blood or buccal swabs
Volume
5 mL of whole blood or four buccal swabs
Minimum Volume
3 mL of whole blood or four buccal swabs
Container
Lavender-stopper (EDTA) tube or paper envelope for dried buccal swabs
Storage Instructions
Maintain at room temperature or refrigerate
Cause for Rejection
Hemolyzed specimen; quantity not sufficient
Use
N-Acetyltransferase 2 (NAT2) catalyzes the activation and/or deactivation of a variety of aromatic amine drugs and carcinogens. Substrates include isoniazod, procainamide, hydralazine, and nitrazepam. Detecting variants of the NAT2 gene that cause altered enzymatic activity can identify patients who may be at increased risk of having adverse drug reactions or therapeutic failure to standard dosages of NAT2 substrates. The assay detects the 7 most frequent single nucleotide polymorphisms of the NAT2 gene: 191G>A, 282C>T, 341T>C, 481C>T, 590G>A, 803A>G, and 857G>A.
.
Limitations
Other variants of the NAT2 gene that are not detected in this assay may influence drug metabolism. NAT2 metabolic capacity is also influenced by concomitant medications, inhibitors, inducers, diet, environmental agents, and various disease states. All factors should be considered as part of the overall patient management strategy.
Methodology
Polymerase chain reaction-allele specific primer extension (FlexMAP system on Luminex instrument).
Turnaround Time
Five business days after receipt of specimen. STAT turnaround time of 3 business days is available for an additional charge.
